XML 90 R76.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue Recognition - Additional Information (Detail) $ in Thousands | 1 Months Ended | 11 Months Ended | 12 Months Ended
--- | --- | --- | ---
Apr. 30, 2022 USD ($) item | Jan. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2024 USD ($) item | Dec. 31, 2023 USD ($) item | Dec. 31, 2022 USD ($) item | Dec. 31, 2018 item
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Accounts receivable, net - related party |  |  |  | $ 407 | $ 2,765 |  |
Total revenue |  |  |  | 7,137 | 20,968 | $ 41,867 |
Accrued professional fees and other |  |  |  | 1,909 | 3,147 |  |
Other receivables |  |  |  | 4,088 | 555 |  |
Receivable for additional HCR financing earned |  |  |  | 2,500 |  |  |
HCR Agreement [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Receivable for additional HCR financing earned |  |  |  | 2,500 |  |  |
Collaborative revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 2,086 | 12,936 | 16,572 |
Commercial supply revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 640 | 5,843 | 10,223 |
License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  | 910 | 15,000 |
Royalty revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  | 415 | $ 72 |
Clinical compound revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 84 | 165 |  |
Other revenue (non-cash) [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 4,327 | 699 |  |
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Number of performance obligations for revenue recognized | item |  |  |  |  |  |  | 2
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] | License and milestone fees [Member] | Regulatory Milestones [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Number Of Combined Performance Obligation At Contract Inception | item | 1 |  |  |  |  |  |
CSL Vifor, Maruishi and CKDP Agreements [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Other contract Assets |  |  |  | $ 0 | $ 0 |  |
CSL Vifor and CKDP Agreements [Member] | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Number of performance obligations for revenue recognized | item |  |  |  | 1 | 1 | 1 |
Maruishi Agreement [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Other receivables |  |  |  | $ 1,047 | $ 415 |  |
Remaining performance obligations |  |  |  | 0 |  |  |
Maruishi Agreement [Member] | Regulatory Milestones [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  | 1,449 |  |
Maruishi Agreement [Member] | Collaborative revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 0 | 539 | $ 0 |
Maruishi Agreement [Member] | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 0 | 910 | 0 |
Maruishi Agreement [Member] | Clinical compound revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 84 | 165 | 0 |
Maruishi Agreement [Member] | Other revenue (non-cash) [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 2,835 | 415 |  |
CSL Vifor | License and milestone fees [Member] | Regulatory Milestones [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue | $ 15,000 |  |  |  |  |  |
Affiliated Entity [Member] | CSL Vifor Profit Sharing | Collaborative revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 2,086 | 12,397 | 16,572 |
Affiliated Entity [Member] | CSL Vifor | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  |  | 15,000 |
Affiliated Entity [Member] | CSL Vifor Kapruvia [Member] | Royalty revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  | 415 | 72 |
Affiliated Entity [Member] | CSL Vifor Kapruvia [Member] | Other revenue (non-cash) [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 1,492 | 284 |  |
Affiliated Entity [Member] | CSL Vifor |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Accounts receivable, net - related party |  |  |  | 407 | 2,765 |  |
Affiliated Entity [Member] | CSL Vifor | Commercial supply revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | 640 | 5,843 | 10,223 |
Affiliated Entity [Member] | CSL Vifor | Commercial Supply Revenue With No Associated Costs Of Goods Sold [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  | $ 2,295 |  |  |  |  |
Cost of goods sold |  | $ 0 |  |  |  |  |
Affiliated Entity [Member] | CSL Vifor | Commercial Supply Revenue With Associated Costs Of Goods Sold [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | $ 7,928 | 640 | 5,843 |  |
Cost of goods sold |  |  | $ 7,266 | 620 | 6,174 |  |
Affiliated Entity [Member] | CSL Vifor | License and milestone fees [Member] |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  |  |  | 15,000 |
Affiliated Entity [Member] | CSL Vifor | CSL Vifor Profit Sharing | Collaborative revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Negative profit share for the Company |  |  |  | 1,639 |  |  |
Affiliated Entity [Member] | CSL Vifor | Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 [Member] | Clinical compound revenue |  |  |  |  |  |  |
Collaboration Arrangement [Line Items] |  |  |  |  |  |  |
Total revenue |  |  |  | $ 0 | $ 0 | $ 0 |

X
- Definition The amount of negative profit share for the company. + References No definition available. + Details
Name: | cara_NegativeProfitShareForCompany
Namespace Prefix: | cara_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of combined performance obligation at contract inception. + References No definition available. + Details
Name: | cara_NumberOfCombinedPerformanceObligationAtContractInception
Namespace Prefix: | cara_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of performance obligations for revenue recognized. + References No definition available. + Details
Name: | cara_NumberOfPerformanceObligationsForRevenueRecognized
Namespace Prefix: | cara_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reflects the amount earned related to the additional milestone receivable under royalty purchase and sale agreement. + References No definition available. + Details
Name: | cara_RoyaltyPurchaseAndSaleAgreementAdditionalMilestoneReceivablesEarned
Namespace Prefix: | cara_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedProfessionalFeesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer. + References No definition available. + Details
Name: | us-gaap_OtherReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cara_HcrAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_CollaborativeRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_LicenseAndMilestoneFeesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_ClinicalCompoundRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_OtherRevenueNonCashMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_ViforFreseniusMedicalCareRenalPharmaLtdAgreementNo2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=cara_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforMaruishiAndCkdpAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforAndCkdpAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_LicenseAgreementWithMaruishiPharmaceuticalCompanyLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforProfitSharingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cara_CslViforKapruviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cara_CslViforMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueWithNoAssociatedCostsOfGoodsSoldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cara_CommercialSupplyRevenueWithAssociatedCostsOfGoodsSoldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |